Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28740851 | 0.92 | CD38 (0.41) | AURKARPS6KB1AURKBPARP1FABP3 | |
| SCHEMBL27531229 | 0.88 | PTGDR2 (0.38) | PARP1C5AR1 | |
| SCHEMBL27506000 | 0.88 | PARP1 (0.36) | PARP1KIF11 | |
| SCHEMBL27507603 | 0.88 | FABP4 (0.40) | FABP4 | |
| SCHEMBL27506443 | 0.86 | KIF11 (0.41) | AURKARPS6KB1AURKBPARP1FABP3 | |
| SCHEMBL27530189 | 0.86 | CYP3A4 (0.39) | AURKARPS6KB1AURKBPARP1FABP3 | |
| SCHEMBL27530624 | 0.86 | KIF11 (0.42) | AURKARPS6KB1AURKBPARP1FABP3 | |
| SCHEMBL27507584 | 0.86 | CYP3A4 (0.39) | AURKARPS6KB1AURKBPARP1FABP3 | |
| SCHEMBL7417015 | 0.86 | L3MBTL1 (0.43) | AURKARPS6KB1PARP1FABP3FABP4 | |
| SCHEMBL27525890 | 0.85 | FABP4 (0.42) | FABP4CYP3A4CD38RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102271507-A | Secreted phospholipase A2(SPLA2) Inhibitor and niacin pharmaceutical composition and method for treating cardiovascular diseases and dyslipidemia | — | 2011-12-07 | — | — | CN | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | disclosed |